Cefonicid vs. cefoxitin for cesarean section prophylaxis.
A randomized, prospective study compared a long-acting, second-generation cephalosporin, cefonicid (Monocid), with a short-acting, second-generation cephalosporin, cefoxitin (Mefoxin), for cesarean section prophylaxis. One hundred thirty-nine patients were enrolled, with 81 receiving a 1-g intravenous dose of cefonicid after cord clamping and 58 receiving a 2-g dose of intravenous cefoxitin after cord clamping and at 6, 12 and 18 hours postpartum. In those patients receiving cefonicid prophylaxis, endometritis incidence was 17.3% (14 of 81). This finding was not statistically significant (P less than .397) when compared to the 12.1% incidence of endometritis (7 of 58) with cefoxitin. In addition, the febrile morbidity incidence for cefonicid prophylaxis was 23.5% (19 of 81) as compared to 15.5% (9 of 58) for cefoxitin (P less than .25). Because the two drugs appear to be equally efficacious, cefonicid may be the better choice because of its markedly lower cost.
Department of Obstetrics and Gynecology, University Hospital of Jacksonville, Florida 32209.
R A
RA
Hartert
G
G
Benrubi
R J
RJ
Thompson
R C
RC
Nuss
D000328:Adult; D000367:Age Factors; D002435:Cefamandole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015790:Cefonicid; D002440:Cefoxitin / Q000627:therapeutic use*; D002585:Cesarean Section / Q000009:adverse effects*; D004716:Endometritis / Q000191:economics / Q000517:prevention & control*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011446:Prospective Studies; D011897:Random Allocation; D012307:Risk Factors; D012959:Socioeconomic Factors
D002435:Cefamandole; D015790:Cefonicid; D002440:Cefoxitin